A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adults
AbbVie
Summary
The objective of this study is to evaluate the safety and efficacy of AGN-151586 for the treatment of moderate to severe forehead lines (FHL) in adult participants.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participant must have moderate (Grade 2) or severe (Grade 3) forehead lines (FHL) at maximum eyebrow elevation as assessed by the subject and investigator using Forehead Lines Severity Scale (FHLSS) at Screening visit and Baseline Day 1 visit. * Participant must have moderate (Grade 2) or severe (Grade 3) glabellar lines (GL) at maximum frown as assessed by the subject and investigator using Allergan Glabellar Lines Severity Scale (AGLSS) at Screening visit and Baseline Day 1 visit. * Sufficient visual acuity without the use of eyeglasses (contact lens use is acceptable)…
Interventions
- DrugAGN-151586
Injection
Locations (5)
- Eye Research Foundation /ID# 282193Newport Beach, California
- Private Practice - Dr. Steven G. Yoelin /ID# 282334Newport Beach, California
- Luxurgery /ID# 282336New York, New York
- Wilmington Dermatology Center /ID# 282192Wilmington, North Carolina
- Austin Institute for Clinical Research - Pflugerville /ID# 282195Pflugerville, Texas